Fenwick v. Ranbaxy Pharm., Inc., 353 F. Supp. 3d 315

Background

Plaintiffs filed a putative nationwide class action seeking refunds for Ranbaxy-manufactured generic atorvastatin lots voluntarily recalled in November 2012 due to possible glass contamination; 41 lots were recalled and ~480,425 bottles were implicated, of which ~400,201 were returned at retail.
The recall was retail-level and FDA-classified Class II; FDA and Ranbaxy advised consumers the health risk was remote and patients should not stop taking medication without medical advice.
Plaintiffs allege recalled bottles were mixed into distributor and pharmacy "inventory pools" with non-recalled bottles, rendering all pills in those pools "substandard," and seek to represent consumers who received pills identified by four NDCs during specified date ranges.
Defendants contend class certification must fail because class representatives lack standing (many did not prove they received contaminated pills) and the proposed class is not ascertainable because lot numbers (not NDCs) determine contamination and most dispensing records lack lot-level traceability.
The Court found three named plaintiffs had standing (two had lot-confirmed recalled bottles; one was told by her pharmacist her bottle matched a recalled lot), but denied class certification because plaintiffs failed to prove the class is ascertainable and failed the predominance inquiry (choice-of-law variations across states for warranty claims).

Issues

Issue	Plaintiff's Argument	Defendant's Argument	Held
Article III standing of class representatives	Plaintiffs say named reps purchased recalled/defective pills (some bottles matched recalled lot numbers); injury is receipt of noncompliant product and loss of refund.	Defendants say plaintiffs have no cognizable injury absent proof their specific bottles were contaminated; uncertainty theory is insufficient.	Court: Three named reps (Safran, Harding, Young) demonstrated standing; overall standing inquiry passes for those reps.
Ascertainability / identification of class members	Plaintiffs propose identifying class members via NDCs, distribution-chain timing, and expert methodology to isolate tainted inventory-pool sales dates.	Defendants say NDCs do not identify lots; retail and distributor records are incomplete; plaintiffs’ expert used samples and cannot reliably identify individual consumers.	Court: Plaintiffs failed by preponderance to show an administratively feasible, reliable method to identify class members; class is not ascertainable.
Predominance (Rule 23(b)(3)) / choice of law for warranty claims	Plaintiffs urge New Jersey law controls (Ranbaxy HQ/recall management in NJ) and common issues predominate for warranty/unjust enrichment claims.	Defendants stress multi-state sales; each purchaser’s contract claim implicates home-state law differences on reliance, privity, notice, and recoverable damages, defeating predominance.	Court: Laws governing express and implied warranty vary across states; each purchaser’s home state governs those contract claims. Predominance not satisfied; unjust enrichment claims will be governed by New Jersey law but that does not salvage certification.
Class definition / inclusion-exclusion by "not known with certainty to have received non-recalled pills"	Plaintiffs’ class excludes anyone known with certainty to have received non-recalled lots and proposes subclasses by dispenser.	Defendants argue it is infeasible to identify and exclude consumers known to have received non-recalled lots because lot-level tracking was not maintained.	Court: Because exclusion cannot be reliably applied and many records lack lot data, the proposed class would inevitably include persons who did not receive recalled product; definition is unworkable.

Key Cases Cited

Mielo v. Steak 'N Shake Operations, Inc., 897 F.3d 467 (3d Cir. 2018) (Article III standing in class actions focuses on class representatives)
Spokeo, Inc. v. Robins, 136 S. Ct. 1540 (U.S. 2016) (standing requires a concrete and particularized injury)
Neale v. Volvo Cars of N. Am., LLC, 794 F.3d 353 (3d Cir. 2015) (class representatives must have Article III standing)
Hassine v. Jeffes, 846 F.2d 169 (3d Cir. 1988) (lack of standing by class representatives mandates dismissal rather than denial of certification)
Marcus v. BMW of N. Am., LLC, 687 F.3d 583 (3d Cir. 2012) (plaintiff bears burden to prove Rule 23 elements by a preponderance; rigorous analysis required)
Byrd v. Aaron's Inc., 784 F.3d 154 (3d Cir. 2015) (ascertainability requires objective definition and administratively feasible means to identify class members)
Carrera v. Bayer Corp., 727 F.3d 300 (3d Cir. 2013) (administrative feasibility and limits on individualized inquiries for ascertainability)
Comcast Corp. v. Behrend, 569 U.S. 27 (U.S. 2013) (plaintiff must affirmatively demonstrate Rule 23 compliance; damages model must align with liability)
Amchem Prods. v. Windsor, 521 U.S. 591 (U.S. 1997) (predominance and predominance’s stringency in mass tort/class contexts)
Tyson Foods, Inc. v. Bouaphakeo, 136 S. Ct. 1036 (U.S. 2016) (distinguishing common vs. individual questions under predominance)
Cole v. GMC, 484 F.3d 717 (5th Cir. 2007) (necessity of extensive analysis of state-law variations in multi-state class actions)
Grandalski v. Quest Diagnostics Inc., 767 F.3d 175 (3d Cir. 2014) (choice-of-law and significance of state-law variations for nationwide classes)